Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

FDA Reviews Prochieve Application

By Drug Discovery Trends Editor | June 27, 2011

LIVINGTON, N.J. (AP) – Watson Pharmaceuticals Inc. said on June 27 that the Food and Drug Administration (FDA) has accepted its marketing application for a progesterone gel that is designed to reduce the risk of premature birth.

Watson said it expects the FDA to make a decision on Prochieve, by Feb. 26, 2012. Prochieve is designed to be applied directly to the cervix during the second trimester of pregnancy, and it is intended for women who have an unusually short cervix, which puts them at higher risk for premature birth. The drug is already approved as a treatment for secondary amenorrhea, or the lack of a menstrual period.

Prochieve was developed and marketed by Columbia Laboratories Inc., based in Livingston, N.J. Watson acquired the drug in July. It paid Watson $47.5 million upfront, and the acceptance of its marketing application triggers another $5 million payment to Columbia Labs. The deal could be worth as much as $92.5 million, and Columbia Labs would also get royalties on sales if the application is approved.

Columbia Labs had asked the FDA to conduct a six-month priority review of Prochieve, but Watson said it withdrew that application.

The Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50